Literature DB >> 4825231

A biochemical abnormality in cerebrotendinous xanthomatosis. Impairment of bile acid biosynthesis associated with incomplete degradation of the cholesterol side chain.

T Setoguchi, G Salen, G S Tint, E H Mosbach.   

Abstract

Bile acid production in cerebrotendinous xanthomatosis (CTX) is subnormal, yet the activity of cholesterol 7alpha-hydroxylase, the rate-determining enzyme of bile acid synthesis, is elevated. To explain this discrepancy, bile acid precursors were sought in bile and feces of three CTX subjects. Over 10% of the total sterols excreted in bile and feces consisted of compounds more polar than cholesterol. Chromatographic analysis of the polar fractions in conjunction with gasliquid chromatography (GLC)-mass spectrometry indicated two major constituents, 5beta-cholestane-3alpha,7alpha,12alpha,25-tetrol and 5beta-cholestane-3alpha,7alpha,12alpha,24xi,25-pentol. After i.v. injection of [4-(14)C]cholesterol both bile alcohols were radioactive proving that they were derived from cholesterol. The accumulation of alcohols hydroxylated at C-25 and C-24,25 suggests that decreased bile acid synthesis in CTX results from impaired oxidation of the cholesterol side chain. This finding and the virtual absence of intermediates hydroxylated at C-26 indicate that current views of the major pathway of bile acid synthesis may require revision.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4825231      PMCID: PMC302628          DOI: 10.1172/JCI107688

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  14 in total

1.  Mass spectrometry in structural and stereochemical problems. CXXV. Mass spectrometry of some steroid trimethylsilyl ethers.

Authors:  J Diekman; C Djerassi
Journal:  J Org Chem       Date:  1967-04       Impact factor: 4.354

Review 2.  Hepatic synthesis of bile acids. Biochemical steps and mechanisms of rate control.

Authors:  E H Mosbach
Journal:  Arch Intern Med       Date:  1972-10

3.  Oxidation of 5 beta-cholestane-3alpha, 7alpha, 12alpha-triol by rat liver microsomes.

Authors:  T Cronholm; G Johansson
Journal:  Eur J Biochem       Date:  1970-10

4.  Cholestanol deposition in cerebrotendinous xanthomatosis. A possible mechanism.

Authors:  G Salen
Journal:  Ann Intern Med       Date:  1971-12       Impact factor: 25.391

5.  25-hydroxyergocalciferol: a biologically active metabolite of vitamin D2.

Authors:  T Suda; H F DeLuca; H Schnoes; J W Blunt
Journal:  Biochem Biophys Res Commun       Date:  1969-04-29       Impact factor: 3.575

6.  Stero-bile acids and bile alcohols. 93. Metabolism of 5-beta-cholestane-3-alpha, 7-alpha, 12-alpha, 25-tetrol.

Authors:  T Yamada
Journal:  Hiroshima J Med Sci       Date:  1966-12

7.  Biosynthesis of 5 -cholestan-3 -ol in cerebrotendinous xanthomatosis.

Authors:  G Salen; A Polito
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

8.  Improved estimation of body masses and turnover of cholesterol by computerized input--output analysis.

Authors:  P Samuel; S Lieberman
Journal:  J Lipid Res       Date:  1973-03       Impact factor: 5.922

9.  Three-pool model of the long-term turnover of plasma cholesterol in man.

Authors:  D S Goodman; R P Noble; R B Dell
Journal:  J Lipid Res       Date:  1973-03       Impact factor: 5.922

10.  Measurements of cholesterol turnover, synthesis, and absorption in man, carried out by isotope kinetic and sterol balance methods.

Authors:  S M Grundy; E H Ahrens
Journal:  J Lipid Res       Date:  1969-01       Impact factor: 5.922

View more
  25 in total

1.  Bile alcohol metabolism in man. Conversion of 5beta-cholestane-3alpha, 7alpha,12alpha, 25-tetrol to cholic acid.

Authors:  G Salen; S Shefer; T Setoguchi; E H Mosbach
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

2.  Case of cerebrotendinous xanthomatosis. I: Unusual ophthalmic features.

Authors:  S J Morgan; P McKenna; R C Bosanquet
Journal:  Br J Ophthalmol       Date:  1989-12       Impact factor: 4.638

3.  Effects of clofibrate on some microsomal hydroxylations involved in the formation and metabolism of bile acids in rat liver.

Authors:  B O Angelin; I Björkhem; K Einarsson
Journal:  Biochem J       Date:  1976-05-15       Impact factor: 3.857

Review 4.  Bile acid biosynthesis. Pathways and regulation.

Authors:  E H Mosbach; G Salen
Journal:  Am J Dig Dis       Date:  1974-10

5.  Biosynthesis of bile acids in man. Hydroxylation of the C27-steroid side chain.

Authors:  I Björkhem; J Gustafsson; G Johansson; B Persson
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

6.  A novel mutation in the sterol 27-hydroxylase gene of a woman with autosomal recessive cerebrotendinous xanthomatosis.

Authors:  Hauke Schneider; Alexandra Lingesleben; Hans-Peter Vogel; Rita Garuti; Sebastiano Calandra
Journal:  Orphanet J Rare Dis       Date:  2010-10-06       Impact factor: 4.123

7.  Cholic acid biosynthesis: the enzymatic defect in cerebrotendinous xanthomatosis.

Authors:  G Salen; S Shefer; F W Cheng; B Dayal; A K Batta; G S Tint
Journal:  J Clin Invest       Date:  1979-01       Impact factor: 14.808

8.  A case of cerebrotendinous xanthomatosis. II: The sterol content of a cataractous lens.

Authors:  P McKenna; S J Morgan; R C Bosanquet; M F Laker
Journal:  Br J Ophthalmol       Date:  1990-10       Impact factor: 4.638

9.  Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease.

Authors:  K D Setchell; M Schwarz; N C O'Connell; E G Lund; D L Davis; R Lathe; H R Thompson; R Weslie Tyson; R J Sokol; D W Russell
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

10.  Demonstration of 26-hydroxylation of C27-steroids in human skin fibroblasts, and a deficiency of this activity in cerebrotendinous xanthomatosis.

Authors:  S Skrede; I Björkhem; E A Kvittingen; M S Buchmann; S O Lie; C East; S Grundy
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.